EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanobodies: Pioneering Next‐Generation Tools in Modern Medicine

Oginni Gbenga Folorunsho, Queenie Fernandes iD, Ayo Oisagah Ezekiel, Anand Babu Wilson

Drug Development Research · 2026

DOI: 10.1002/ddr.70319 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Development Research, 2026. Verfasst von Oginni Gbenga Folorunsho und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia. Hauptthemen laut MEDLINE: Single-Domain Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 163 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanobodies, also known as single‐domain antibodies or Variable Heavy domain of Heavy chain antibody, are unique antibody fragments derived from camelid heavy‐chain antibodies. Due to their small size, stability, and high specificity, nanobodies have gained significant attention for therapeutic and diagnostic applications across various diseases, including cancer, infectious diseases, and neurodegenerative disorders. Their structural simplicity allows efficient production in microbial systems, offering a scalable and cost‐effective alternative to traditional monoclonal antibodies. In cancer, nanobodies are effective for targeted drug delivery, improved tumor imaging, and enhanced penetration into solid tumors. Moreover, the versatility of engineered nanobodies extends to the treatment of neurodegenerative diseases, where they may possess the ability to cross the blood‐brain barrier, allowing for targeted delivery within the central nervous system. Additionally, nanobodies demonstrate promise in neutralizing toxins, inhibiting inflammatory responses, and modulating the immune system, showcasing their adaptability in treating infectious and inflammatory diseases. Despite their advantages, challenges such as limited half‐life, potential immunogenicity, and regulatory hurdles remain. This review explores the structural and functional characteristics of nanobodies, their applications in various disease therapies, and current strategies to overcome these therapeutic limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Single-Domain AntibodiesHumansAnimalsNeoplasmsDrug Delivery SystemsNeurodegenerative DiseasesProtein Engineering

Stichwörter der Autor:innen

cancer therapyengineered antibodiesnanobodiesneurodegenerative disease therapysingle‐domain antibodiestargeted drug delivery

Substanzen

Single-Domain Antibodies

Autor:innen und Institutionen

  • Laboratory of Environmental and Life Sciences, University of Nova Gorica, Nova Gorica, Slovenia.
  • Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
  • Department of Biological Sciences, Joseph Ayo Babalola University, Ikeji-Arakeji, Osun State, Nigeria.
  • Department of Medicine, University of Verona, and Azienda Ospedaliera Universitaria Verona, Policlino GB Rossi, Verona, Italy.

ORCID-Profile: Queenie Fernandes

Zitieren

APA

Folorunsho, O. G., Fernandes, Q., Ezekiel, A. O., & Wilson, A. B. (2026). Nanobodies: Pioneering Next‐Generation Tools in Modern Medicine. Drug Development Research. https://doi.org/10.1002/ddr.70319

Vancouver

Folorunsho OG, Fernandes Q, Ezekiel AO, Wilson AB. Nanobodies: Pioneering Next‐Generation Tools in Modern Medicine. Drug Development Research. 2026. doi:10.1002/ddr.70319

BibTeX
@article{Folorunsho2026,
  author = {Folorunsho, Oginni Gbenga and Fernandes, Queenie and Ezekiel, Ayo Oisagah and Wilson, Anand Babu},
  title = {Nanobodies: Pioneering Next‐Generation Tools in Modern Medicine},
  journal = {Drug Development Research},
  year = {2026},
  doi = {10.1002/ddr.70319}
}
Kostenlos starten →